- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04987775
GWICTIC: NAC Mechanistic Study in Gulf War Veterans (NAC)
Mechanisms of Oxidative Stress During N-Acetyl Cysteine (NAC) Supplementation in Veterans With Gulf War Illness (GWI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
During the 1990-91 Gulf War (GW), military personnel were exposed to numerous chemical and environmental agents during deployment including spraying of pesticides, petroleum combustion products, and nerve gas. Exposure to these chemical and environmental agents can damage cell function and more specifically, mitochondrial function, which negatively affects energy production and can lead to oxidative stress and neuroinflammation. Animal models using similar exposures have documented this in the central nervous system (CNS) compartment. This disruption in mitochondrial function and energy production is likely tied to resulting symptoms of Gulf War Illness (GWI) including fatigue, headaches, joint and muscle pain, gastrointestinal and sleep disturbances, neurologic and neuropsychological symptoms, respiratory issues, and cardiovascular problems.
The Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC) plans to evaluate N-Acetyl Cysteine (NAC) as a promising approach to help the CNS recover from chronic oxidative stress and depletion of antioxidants. The Congressionally Directed Medical Research Program's (CDMRP's) two Gulf War Illness Consortiums (GWICs) and others have added to the growing evidence of the role of CNS oxidative stress and neuroinflammation in symptoms of GWI, yet there is little definitive work on the delivery of antioxidants to the CNS environment. In this mechanistic study, we aim to determine if NAC has the ability to target mitochondrial dysfunction and reverse oxidative stress in the CNS. Based on our early experiences with antioxidants in GWI and other complex disease states along with the proven record of NAC in reducing glutathione (GSH) deficits, it is possible that this antioxidant will help to restore mitochondrial function and provide a more targeted approach to improve outcomes in Veterans with GWI.
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Nancy Klimas, MD
- Phone Number: 9542622855
- Email: nklimas@nova.edu
Study Contact Backup
- Name: Karen Kesler, PhD
- Email: kkelser@rti.org
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Recruiting
- VA Palo Alto Health Care System War Related Illness and Injury Study Center
-
Contact:
- Wes Ashford, MD
- Phone Number: 650-852-3316
- Email: wes.ashford@va.gov
-
Principal Investigator:
- Wes Ashford, MD
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33314
- Recruiting
- Nova Southeastern University
-
Principal Investigator:
- Nancy Klimas, MD
-
Contact:
- Nancy Klimas, MD
- Email: nklimas@nova.edu
-
Contact:
- Amaanpreet Cheema, PhD
- Email: acheema@nova.edu
-
Sub-Investigator:
- Amaanpreet Cheema, PhD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Boston University Medical School
-
Contact:
- Kimberly Sullivan, PhD
- Phone Number: 617-358-2168
- Email: tty@bu.edu
-
Principal Investigator:
- Kimberly Sullivan, PhD
-
Sub-Investigator:
- Anna Cervantes-Arslanian, MD
-
Sub-Investigator:
- Bang-bon Koo, PhD
-
Sub-Investigator:
- Maxine Krengel, PhD
-
-
New Jersey
-
East Orange, New Jersey, United States, 07018
- Recruiting
- VA New Jersey Health Care System War Related Illness and Injury Study Center
-
Contact:
- Helena Chandler, PhD
- Phone Number: 973-676-3580
- Email: Helena.Chandler@va.gov
-
Principal Investigator:
- Helena Chandler, PhD
-
-
New York
-
New York, New York, United States, 10021
- Active, not recruiting
- Weill Cornell Medical College
-
-
North Carolina
-
Durham, North Carolina, United States, 27709
- Active, not recruiting
- RTI International
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Michael E. DeBakey VA Medical Center
-
Contact:
- Drew Helmer, MD
- Phone Number: 713-440-4452
- Email: Drew.Helmer@va.gov
-
Principal Investigator:
- Drew Helmer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 47 to 70 years
- Served in the Gulf War Theater for any period between August 1990 and July 1991.
Meets modified Kansas case definition criteria for Gulf War Illness. The modified Kansas definition includes the following:
- Allowance of normal illness of aging, such as hypertension and diabetes, if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment.
- Allowance of stable comorbid conditions such as Post Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and mild Traumatic Brain Injury (mTBI) that have not required hospitalization in the 2 years prior to recruitment. Severe TBI is excluded.
- Able to provide written consent to the study
- Agrees to participate in follow-up visits.
Exclusion Criteria:
- Self-report of current treated or untreated major depression with psychotic or melancholic features (as determined by self-report and Hamilton Depression Inventory (Ham-D)), schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or a history of central nervous system (CNS) disorders that may affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease), or alcoholism or drug abuse
- Severe claustrophobia or serious difficulty being in an MRI scanner or other enclosed space (MRS substudy only)
- Presence of ferrous implanted medical devices or metal fragments or objects that are embedded under the skin (MRS substudy only)
- Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day.
- Chronic active infections such as HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (self-report or antibody titer)
- Renal disease (self-report or laboratory results: renal insufficiency with serum creatinine > 2.0 mg/dL)
- Liver disease (self-report or laboratory results: hepatic insufficiency (bilirubin >2.5mg/dL or transaminases > 3 times the upper limits of normal)
- Uncontrolled diabetes (HgbA1c > 7.5) without adequate medical care. Individuals with HgbA1c > 7.5 will be reviewed and judged by the PI or delegate; if potential participant has adequate medical care to manage diabetes, enrollment is allowed; otherwise HgbA1c > 7.5 is exclusionary
- Diagnosed vascular disease (including congestive heart failure)
- Diagnosed bleeding disorders or use of blood-thinning medications
- Receipt of stavudine or didanosine for more than 7 days within 30 days prior to screening
- Currently have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity
- Are scheduled for a surgery during the period of study participation or had surgery within 6 weeks prior to screening
- Pregnant (women only)
Prohibited Concomitant or Prior Therapies
- Currently on dialysis
- Previous or current receipt of any antiviral medication, such as pegylated interferon, ribavirin, entecavir, tenofovir, or didanosine for more than 7 days within 30 days prior to screening
- Participating in another interventional (including social-behavioral therapy) clinical trial of an investigational therapy within 6 weeks prior to consent, or planning to participate in another interventional clinical trial of an investigational therapy during the course of this study
- Any herbal medicine within 30 days prior to consent and screening blood draw
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: N-Acetyl Cysteine (NAC)
Participants who are randomized to the intervention arm will receive N-Acetyl-L-Cysteine (Free-Form/NAC) 900mg two times a day for 8 weeks after the initiation of the first dose of study drug.
|
900mg 2x daily
Other Names:
|
Placebo Comparator: Placebo
Participants who are randomized to the placebo arm will take matching placebo two times a day for 8 weeks after the initiation of the first dose of study drug.
|
Matching placebo bid
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess glutathione levels
Time Frame: Baseline to 8 weeks
|
Change in glutathione levels after NAC supplementation compared to placebo in participants with gulf war illness (GWI)
|
Baseline to 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glutathione levels
Time Frame: Baseline to 8 Weeks
|
Measure the change of brain glutathione levels with magnetic resonance spectroscopy (MRS) in a subset of both arms of study at baseline and 8 weeks.
|
Baseline to 8 Weeks
|
Change in number of participants with treatment-related adverse events
Time Frame: Baseline to 16 Weeks
|
Change in number of participants with treatment-related adverse events from baseline to 16 weeks during the intervention period as assessed by a safety questionnaire.
|
Baseline to 16 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nancy Klimas, MD, Nova Southeastern Univeristy
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Wounds and Injuries
- Occupational Diseases
- War-Related Injuries
- Persian Gulf Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Protective Agents
- Respiratory System Agents
- Antioxidants
- Antidotes
- Free Radical Scavengers
- Expectorants
- Acetylcysteine
- N-monoacetylcystine
Other Study ID Numbers
- GWICTIC-NAC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gulf War Syndrome
-
American UniversityBoston University; Massachusetts General Hospital; Georgetown University; Nova...RecruitingGulf War Syndrome | Gulf War IllnessUnited States
-
Roskamp Institute Inc.Boston University; United States Department of Defense; Palo Alto Veterans Institute...Recruiting
-
University of UtahVA Salt Lake City Health Care SystemWithdrawn
-
Baylor College of MedicineTexas A&M University; Michael E. DeBakey VA Medical CenterNot yet recruiting
-
Georgetown UniversityU.S. Army Medical Research and Development CommandCompletedGulf War Illness | Persian Gulf War SyndromeUnited States
-
South Florida Veterans Affairs Foundation for Research...Unknown
-
VA Office of Research and DevelopmentCompleted
-
University of Alabama at BirminghamCongressionally Directed Medical Research ProgramsRecruiting
-
Baylor College of MedicineMichael E. DeBakey VA Medical CenterTerminated
-
The University of Texas at DallasUnited States Department of Defense; University of Texas Southwestern Medical...TerminatedGulf War SyndromeUnited States
Clinical Trials on N-Acetyl Cysteine
-
Universidade Estadual de MaringáUnknownBipolar DisorderBrazil
-
Minia UniversityUnknown
-
University of Colorado, DenverWithdrawn
-
Aga Khan UniversityNational Institute of Liver & GI Diseases, PakistanNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnHead and Neck Cancer
-
Imam Khomeini HospitalTehran Heart CenterUnknownRadiographic Contrast Agent Nephropathy | Chronic Kidney Disease Stage 2Iran, Islamic Republic of
-
Nemours Children's ClinicCompletedObesity | Cardiovascular Disease | Nonalcoholic Fatty Liver DiseaseUnited States
-
Washington University School of MedicineSuspendedDiabetes Mellitus | Peripheral Arterial Disease | Critical Limb Ischemia | Lower Limb Amputation KneeUnited States
-
Children's Hospital Medical Center, CincinnatiUnited States Department of DefenseRecruitingNeurofibromatosis 1United States